Last reviewed · How we verify
IDEA-033
IDEA-033 is a small molecule drug that targets the molecular target.
IDEA-033 is a small molecule drug that targets the molecular target. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | IDEA-033 |
|---|---|
| Sponsor | IDEA AG |
| Drug class | small molecule |
| Target | target molecular target |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
IDEA-033 works by binding to the molecular target, which results in the desired therapeutic effect. This mechanism of action is still being researched and more information is needed to fully understand how it works.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Headache
Key clinical trials
- IDEA-033 Open Label Study (PHASE3)
- Ketoprofen in Transfersome Compared to Oral Celecoxib and Placebo for Pain Associated With Osteoarthritis of the Knee (PHASE2)
- IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA (PHASE3)
- An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee (PHASE2)
- A Long-Term Safety Study of IDEA-033 in Comparison to Oral Naproxen for the Treatment of Osteoarthritis of the Knee (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |